SpotiDoc
2015_03_17 Valneva EB66 in China ENG
Valneva announces signing of an exclusive license agreement
on EB66® Cell Line for Human and Veterinary Vaccines in
People's Republic of China
The partner Jianshun Biosciences Ltd is granted exclusive rights to
commercialize the EB66® cell line in People's Republic of China only
Valneva receives EUR 2.5 million upfront payment and is entitled to
further annual license fees and royalties
China's Human vaccine market reached nearly EUR 2 billion (RMB
13.7 billion) in 2012 1, with an average growth rate in the range of
16%-18% expected between 2014 and 2018
Valneva and Jianshun Biosciences Ltd see a significant business
opportunity arising from the growth of the vaccine market and the
technological shift of the Chinese vaccine manufacturing industry,
which will benefit from the EB66® cell line as a modern cell-culture
based production system.
Lyon (France), Lanzhou (People's Republic of China)- March 17, 2015 –Valneva SE
("Valneva"), a leading pure play vaccines biotech company, announced today that it has
signed an exclusive license agreement with the Chinese company Jianshun Biosciences
Ltd to commercialize Valneva's EB66® cell line for the manufacturing of human and
veterinary vaccines in People's Republic of China only.
The Partner, Jianshun Biosciences Ltd, headquartered in Lanzhou (People's Republic of
China), provides bio process and technology services for Chinese biopharmaceutical
companies. Dr. Luo Shun, Founder and President of the company, is one of the
"thousand people plan" 2 experts (thousands of foreign experts, or returning-Chinese
talents) who have been nominated by the Central Government to work in China and
promote innovation and technological development primarily in the high-tech and
financial industries. Dr. Luo Shun worked in the USA for Amgen and for Genentech.
Under the terms of the agreement, Jianshun Biosciences Ltd is granted rights to
sublicense Valneva's EB66® cell line to Chinese vaccine companies which will then be
able to develop, manufacture and commercialize, in the People's Republic of China
Territory only, human and veterinary viral vaccines using the EB66® cell line. All
Research and Investment Prospect of Human Vaccine Industry in China, 2014-2018
See more at: http://www.china-briefing.com/news/2012/11/22/chinas-long-term-plan-to-import-thousandsof-highly-qualified-foreigners.htm l
vaccines against influenza for use in humans are excluded from the license agreement.
Valneva will receive an upfront license payment of EUR 2.5 million and an additional
payment of EUR 0.5 million in 2016, as well as annual maintenance fees and 50% of
total revenues payable to Jianshun Biosciences Ltd from its sub licensees. These
payments should contribute to further improve the profitability of the EB66® cell line in
the coming years.
Valneva remains the full owner of the EB66® platform and will continue to license its
technology outside China.
Thomas Lingelbach, President and Chief Executive Officer and Franck Grimaud,
President and Chief Business Officer of Valneva, commented "This agreement is an
important step forward in the international roll-out of our EB66® platform and we think
this is now the right time to address the Chinese market. We are very pleased to
collaborate with Jianshun Biosciences Ltd and are convinced that Jianshun Biosciences
Ltd and its CEO, Dr Luo Shun, are the right partners to promote our cutting edge
technology among the local vaccine industry, which is booming."
China, as an emerging vaccine market, represents a major opportunity for Valneva. The
government has made a priority to better protect the population from diseases,
especially in endemic areas and China's vaccine manufacturers are moving ahead to
become global suppliers of affordable vaccines. China's human vaccine market is
comprised of 42 vaccine manufacturers and in 2013 the total quantity of vaccines
manufactured in China amounted to about 755 million doses 3. Chinese vaccine
manufacturers consist of state-owned enterprises, private enterprises and foreign-funded
enterprises. The state-owned enterprises take the leading position with a 62% market
share, followed by private enterprises and foreign-funded enterprises with a market
share of 34% and 4% respectively.
To date, Valneva has more than 35 license agreements with the world's largest
pharmaceutical companies for the use of its EB66® vaccine production platform in both
human and animal health vaccines. Valneva's proprietary platform has enabled three
veterinary vaccines and one human vaccine to be commercialized.
Contacts Valneva SE
Florence Hocdée- Leroy
Teresa Pinzolits
M: +43 676 845567357
About Valneva SE
Formed in 2013 through the merger of Intercell AG and Vivalis SA, Valneva is a biotechnology
company developing, manufacturing and commercializing innovative vaccines with a vision to
protect people from infectious diseases. The Company seeks financial returns through focused
R&D investments in promising product candidates and growing financial contributions from
commercial products, striving towards financial self-sustainability.
Valneva´s portfolio includes two commercial vaccines for travelers: one for the prevention of
Japanese encephalitis (IXIARO ) and the second (Dukoral ) indicated for the prevention of and
protection against traveler's diarrhea caused by ETEC (Enterotoxigenic Escherichia coli) and/or
Cholera. The Company has proprietary vaccines in development including candidates against
Pseudomonas aeruginosa, Clostridium difficile and Lyme Borreliosis. A variety of partnerships
with leading pharmaceutical companies complement the Company's value proposition and
include vaccines being developed using Valneva´s innovative and validated technology platforms
(EB66 vaccine production cell line, IC31 adjuvant).
Valneva is headquartered in Lyon, France, listed on Euronext-Paris and the Vienna stock
exchange and operates out of France, Austria, Scotland and Sweden with approximately 400
employees. More information is available at www.valneva.com.
This press release contains certain forward-looking statements relating to the business of
Valneva, including with respect to the progress, timing and completion of research, development
and clinical trials for product candidates, the ability to manufacture, market, commercialize and
achieve market acceptance for product candidates, the ability to protect intellectual property and
operate the business without infringing on the intellectual property rights of others, estimates for
future performance and estimates regarding anticipated operating losses, future revenues, capital
requirements and needs for additional financing. In addition, even if the actual results or
development of Valneva are consistent with the forward-looking statements contained in this
press release, those results or developments of Valneva may not be indicative of the future. In
some cases, you can identify forward-looking statements by words such as "could," "should,"
"may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar
words. These forward-looking statements are based largely on the current expectations of
Valneva as of the date of this press release and are subject to a number of known and unknown
risks and uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from any future results, performance or achievement
expressed or implied by these forward-looking statements. In particular, the expectations of
Valneva could be affected by, among other things, uncertainties involved in the development and
manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or
delays, competition in general, currency fluctuations, the impact of the global and European credit
crisis, and the ability to obtain or maintain patent or other proprietary intellectual property
protection. In light of these risks and uncertainties, there can be no assurance that the forwardlooking statements made in this press release will in fact be realized. Valneva is providing the
information in these materials as of the date of this press release, and disclaims any intention or
obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events, or otherwise.
About Jianshun Biosciences Ltd
Jianshun Biosciences Ltd. is located in the Lanzhou Economic-Technological Development Zone
and was founded in March, 2011. Jianshun Biosciences Ltd. is a newly established company in
China that develops and manufactures serum-free, chemically-defined cell culture media which
includes liquid media and dry powder media. The company also produces media for stem cells
and primary cells.
Jianshun Biosciences, Ltd. has a group of world-class experts, a state of the art facility
(equipment and instruments), a growing market, and high-level cooperative partners as well as
strong government support.
Focusing on research and development, Jianshun Biosciences provides serum-free, chemicallydefined cell culture media to biopharmaceutical companies in China and is capable of providing
customized processes and formulations for its customers.
Confronted with the current situation in the Chinese biotechnology industry, Jianshun Biosciences
has the responsibility to make a contribution. It has both the ability and confidence to work for the
well-being of the Chinese people by producing the highest quality raw materials for the
biopharmaceutical industry.
Valneva Announces Two New Deals on its EB66 Vaccine Cell Line
Artwork without trims if you just want to print a few at home
ecavi_presentation_kpa annual scientific conference_16_ april
} Vaccines Investment in research saves lives and money
Document 248725
Document 58619
Why are we reviewing the evidence on
49 DOSES OF 14 VACCINES BEFORE AGE 6?
2014-2015 Seasonal Flu Vaccination Consent
the Clinical Science Supplies & Requirements
spotidoc.com
About spotidoc